Clinical Trials on EGFR Mutant Advanced Non-small Cell Lung Cancer

Total 7006 results

Intergroupe Francophone de Cancerologie Thoracique
Groupe Français de Pneumo-Cancérologie

Completed

Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

France
Centre Antoine Lacassagne

Completed

A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy (TAXCIS)

Locally Advanced Non-small Cell Lung Cancer
Shandong Simcere-Medgenn Bio-pharmaceutical Co....

Completed

Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
The Norwegian Lung Cancer Study Group

Completed

Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

Norway
Taiho Oncology, Inc.
Quintiles, Inc.; United BioSource, LLC

Completed

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Clovis Oncology, Inc.

Terminated

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Metastatic Lung Cancer | SCLC | Stage IV Lung Cancer | Advanced Lung Cancer | Squamous Non-Small Cell Lung Cancer

United States, Italy, Germany, France, Spain
Ohio State University Comprehensive Cancer Center
National Institute on Aging (NIA)

Recruiting

Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

EGFR-Mutated Non-Small-Cell Lung Carcinoma | Small Cell/Neuroendocrine

United States
Scorpion Therapeutics, Inc.

Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Non-Small Cell Lung Cancer | NSCLC | EGFR/HER2 Exon 20 Insertion Mutation

United States, Taiwan
Zhejiang Teruisi Pharmaceutical Inc.

Unknown

A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC (NSCLC)

Advanced Non-squamous Non-small-cell Lung Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Active, not recruiting

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

EGFR Exon 20 Mutation | ERBB2 Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States, Korea, Republic of, Israel, Japan, China, Australia
Dracen Pharmaceuticals, Inc.

Terminated

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Advanced Solid Tumor | Non Small Cell Lung Cancer Metastatic

United States, Taiwan, Germany, Singapore, Spain
WindMIL Therapeutics
Bristol-Myers Squibb

Terminated

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

NSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Metastatic

United States
The Fourth Affiliated Hospital of Zhejiang University...

Completed

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

NSCLC | EGFR Gene Mutation | Non-small-lung-cell Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Advanced Lung Carcinoma
National Cancer Institute (NCI)

Recruiting

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

United States
Regeneron Pharmaceuticals
BioNTech SE

Recruiting

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, Georgia, Taiwan, Germany, Turkey
Qianfoshan Hospital
Shandong Provincial Hospital

Not yet recruiting

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer (MWA)

Advanced Non Small Cell Lung Cancer

China
NYU Langone Health

Withdrawn

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

United States
Pfizer

Completed

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Advanced Non-Small Cell Lung Cancer

India
Xcovery Holding Company, LLC

Completed

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States
Yongchang Zhang

Completed

Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Advanced/Recurrent Non-small-cell Lung Cancer

Japan
AstraZeneca

Completed

Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m (REASON)

Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer

Germany
InventisBio Co., Ltd

Completed

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

NSCLC | Solid Tumor | EGFR T790M

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Advanced Non-small Cell Lung Cancer
Achilles Therapeutics UK Limited

Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Melanoma | Advanced Non Small Cell Lung Cancer

United Kingdom
Novartis Pharmaceuticals

Completed

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Advanced Non-small Cell Lung Cancer

Spain, Canada, Germany, Korea, Republic of, Taiwan, United States, Japan, Netherlands, Singapore
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
National Cancer Institute, Naples

Completed

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

Advanced Non-small Cell Lung Cancer

Italy
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
University of California, San Francisco
AstraZeneca

Active, not recruiting

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung Cancer

United States
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, China, Korea, Republic of, Belgium, Hong Kong, Japan, Taiwan, Denmark, Germany, Israel, Poland, Italy, United Kingdom, Bulgaria, Czechia, Portugal, Switzerland, Greece, Turkey, Romania, Sweden, France, Singapore, Mexico, ... and more
Hubei Cancer Hospital

Recruiting

Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Non Small Cell Lung Cancer | Radiotherapy | Immunotherapy | Locally Advanced

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Beijing Biostar Pharmaceuticals Co., Ltd.

Recruiting

Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Guangdong Provincial People's Hospital

Not yet recruiting

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Advanced Non-small Cell Lung Cancer

China
AstraZeneca
Parexel

Active, not recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
Institut Claudius Regaud
Merck KGaA, Darmstadt, Germany

Completed

Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Locally Advanced Non Small Cell Lung Cancer (NSCLC)

France
Taiho Oncology, Inc.

Completed

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Advanced or Metastatic Non-small Cell Lung Cancer

United States, France, Poland, Spain, Italy, Japan
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Failed Prior Chemotherapy

United States
Case Comprehensive Cancer Center

Terminated

Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study

Advanced (Stage IV) Non-small Cell Lung Cancer (NSCLC)

United States
Ass. Prof. Jan Nyman

Terminated

Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy (PLANET)

Non Small Cell Lung Cancer | Locally Advanced Disease

Sweden

Clinical Trials on EGFR Mutant Advanced Non-small Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations